Our Pipeline
Clinical
Candidate505(b) (1)
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Next
Milestone
Commentary
EPX-100
DS Single pivotal Study
Complete Enrollment 2Q22
- Topline results expected in 1Q2023
- ODD/RPD for DS granted from the FDA
- NOL released from Health Canada
- CTA approved from MHRA, UK
EPX-100
LGS Single pivotal Study
Complete Enrollment 3Q22
- IND appoved from the FDA
- ODD/RPD for LGS granted from the FDA
- Topline results expected in 2Q2023
EPX-100
Otahara Syndrome
IND Enabling
- ODD/RPD for OS granted from the FDA
EPX-101/102/103
LGS/DS
IND Enabling Studies
- IND enabling tox studies
- Route scouting
- Formulation Develeopment
505(b) (2) EPX-200
LGS/DS
IND Filing
- Human PoC for DS/LGS confirmed
- ODD for DS granted from the FDA
- OMD for DS granted from the FMA
- ODD/RPD for LGS granted from the FDA
EPX-300
LGS/DS
IND Filing
- Human PoC for DS confirmed
- ODD for DS granted from the FDA
EPX-100 is a first-generation antihistamine safely used from the 1950-1970s. EPX-100 is not currently manufactured or available anywhere in the world. EPX-100 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for Dravet Syndrome. EPX-100’s antiepileptic action is not through a histaminergic mechanism of action but acts via modulation of serotonin (5HT) signaling pathways.
EPX-200 is an FDA-approved weight gain management drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-200 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for Dravet Syndrome. Promising clinical results support the efficacy of EPX-200 in terms of the reduction of convulsive seizure frequency and/or severity in a small number of patients with Dravet syndrome.
All of them were a potent suppressor of spontaneous convulsive behavior and electrographic seizures in this model.
EPX-300 is an FDA-approved antidepressant, anti-anxiety and sleep-inducing insomnia drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-300 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for Dravet Syndrome. Human PoC has been confirmed with small no. of patients.